Danish pharmaceutical company Resothera Pharma, which is currently involved in a merger with acquisition company Hunter Capital RTO1, plans to initiate its international Phase 2b study with more than 200 patients in spring 2027. CEO Anders Kronborg says this in an interview.
According to him, the first patient is expected to be enrolled in April or May, while recruitment is expected to be completed in the first quarter of 2028. Study results are expected during the third quarter of the same year.
The company is also in dialogue with several major pharmaceutical companies in the field of cardiology, but potential partners want to see additional clinical data before a collaboration can become relevant.
The financing is expected to last until the final patient has been recruited for the study.
